Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, fentanyl citrate (Breakyl®) cannot be endorsed for use within NHS Wales for the management of breakthrough pain in opioid tolerant adult patients with cancer. |
||
|
||
Medicine details |
||
| Medicine name | fentanyl citrate (Breakyl®) | |
| Formulation | Buccal film | |
| Reference number | 1177 | |
| Indication | Management of breakthrough pain in opioid tolerant adult patients with cancer |
|
| Company | Meda Pharmaceuticals Ltd | |
| BNF chapter | Central nervous system | |
| Assessment type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 11/10/2011 | |